Premium
Precancerous and Cancerous Predictive Signatures Using a Custom Designed Novel Gene Expression Assay
Author(s) -
Vase Hollie Francesca,
Drew Janice,
Farquharson Andrew,
Ross Ruth,
Carey Frank,
Steele Robert
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.397.1
Subject(s) - lgr5 , cancer research , biomarker , multiplex , colorectal cancer , gene expression , biology , serial analysis of gene expression , cancer , adenoma , pathology , gene expression profiling , medicine , gene , bioinformatics , genetics
Cancers exhibit a range of abnormal gene expression signatures associated with disease initiation and progression characterised by specific biomarkers. Identification of these biomarkers has improved cancer screening, detection, drug development and selection of appropriate drug therapies for individual patients. Typically only very small amounts of tissue are available from patient samples for analysis. A custom designed GeXP (Beckman) multiplex gene expression assay, the hCellMarkerPlex, was developed. Total RNA (50ng) from human colon normal, adenoma and carcinoma tissue samples (n=20) was assayed by hCellMarkerPlex. Predictive hCellMarkerPlex signatures of epithelial ( EZR, KRT18, SLC9A2 ), proliferation ( PCNA, CCND1, MS4A12 ), differentiation ( B4GANLT2, CDX1, CDX2 ), apoptotic ( CASP3, NOX1, NTN1 ), fibroblast ( FSP1, COL1A1 ), structural ( ACTG2, CNN1, DES ), gene transcription ( HDAC1 ), stem cell ( LGR5 ), endothelial ( VWF ) and mucin production ( MUC2 ) markers were established. GeXP technology identified gene signatures distinguishing normal, adenoma and carcinoma tissue and identified cellular processes showing abnormal activity associated with pathological status. The resulting biomarker profiles will be of medical use to inform on diagnosis, disease progression and monitoring treatments for colon cancer.